Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials-Reference-Cited by-同舟云学术

Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials

Published:2003-10 Issue:10 Volume:37 Page:1478-1488
ISSN:1060-0280
Container-title:Annals of Pharmacotherapy
language:en
Short-container-title:Ann Pharmacother

Author:

Schentag Jerome J¹,Meagher Alison K²,Forrest Alan³

Affiliation:

1. Jerome J Schentag PharmD, CEO, CPL Associates, LLC; Professor, School of Pharmacy, University at Buffalo, Buffalo, NY

2. Alison K Meagher PharmD, Director of Anti-Infective and Sepsis Research, CPL Associates, LLC

3. Alan Forrest PharmD, Director, Pharmacometrics and Biostatistical Analysis, CPL Associates, LLC Research; Professor of Pharmacy Practice, School of Pharmacy, University at Buffalo; Adjunct Professor of Pharmaceutics, School of Pharmacy, University at Buffalo

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Link

http://journals.sagepub.com/doi/pdf/10.1345/aph.1C419

Reference59 articles.

1. Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates

2. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

3. Comparison of the Fluoroquinolones Based on Pharmacokinetic and Pharmacodynamic Parameters

4. Pharmacodynamics of Levofloxacin

5. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determining in vitro and ex vivo protein binding of levofloxacin and moxifloxacin in patients with TB;The International Journal of Tuberculosis and Lung Disease;2022-12-01

2. Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range;Therapeutic Drug Monitoring;2022-02

3. Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis;Open Forum Infectious Diseases;2021-12-29

4. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia;Antimicrobial Agents and Chemotherapy;2021-05-18

5. Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method;Clinical Biochemistry;2021-04